ALM D Risk mx and lifestyle changes
S2B Lifestyle modifications for cancer & chronic disease prevention & improved outcomes
A panel discussion presenting strategies for improving disease prevention & Mx as they apply in the primary care setting. Chronic diseases are responsible for approximately 70% of the total disease burden in Australia, where approximately 50% of adults live with a chronic condition. Many are preventable & share common risk factors, for which prevention & the design of population–based & high risk approaches for disease prevention are possible. Smoking, nutritional factors & physical inactivity are common determinants to most of these diseases & their integrated control would lead to improved outcomes. Primary care plays a key role in disease prevention & Mx, but traditionally these diseases have been managed individually, rather than with an integrated approach. WA sessions 3,6,12 complement this seminar. Prof Ian Caterson Cancer Council NSW
S3C Diabetes strategies to improve Mx of type 2 diabetes
This seminar will overview current diabetes Mx in Australia; discuss the importance of treating to target & strategies to improve diabetes outcomes; & review the role of early combination therapy & the glycaemic efficacy of glitazones. GlaxoSmithKline
S4C CARDIO & VASCULAR RISK PREVENTION - a 2008 update
This seminar will focus on the practical Mx of patients with a high cardio & vascular risk. It will examine best practice in hypertensive & cardiovascular Mx, reviewing the latest evidence for improving patient outcomes. Dr Greg Conner Boehringer–Ingelheim
S7B Obesity bariatric surgery
In Australia, an estimated 2.5 million adults were obese in 2004–05. If rates continue to soar there could be as many as 7.2 million obese Australians by 2025. This seminar will look at the co–morbidities associated with obesity, who is suitable for bariatric surgery, long term weight loss results & the importance of a multidisciplinary bariatric team. Included will be an overview of statistics; a review of “real” patient case studies & results; & a video of a gastric band adjustment or surgery. You will listen to a patient & his experience. Dr Roy Brancatisano Johnson & Johnson
S9A Lipid disorders update beyond LDL
The seminar will discuss the importance of managing the complete lipid profile, not just treating high LDL. It will cover the benefits of statins in reducing LDL & reducing cardiovascular risk & will highlight the concept of residual risk despite statin therapy. It will examine the risk associated with elevated triglycerides & how fibrates
reduce CV risk in patients with elevated triglycerides. Combination therapy will be discussed in the context of mixed dyslipidaemia, type 2 diabetes. Professor David Sullivan Solvay
S10C Persistent cough is it pertussis?
The most common vaccine preventable disease is pertussis, with 90% of cases now in adults & often missed in gp. The incidence is likely to be much higher than the 11,000 reported last year as 95% of cases go undiagnosed or are mistaken for persistent cough. Pertussis is highly infectious, with over half of cases in infants (which account for 80% of hospitalisations) being transmitted by their parents. Both natural & disease induced immunity wane over time, so close contacts of newborns need a pertussis booster to reduce the risk of passing it on (recommended by NHMRC). Dr Diana Hart Sanofi–Pasteur
S11A Child and adolescent obesity
Childhood obesity is a significant & increasing problem in Australia. Despite this, there is little evidence available that identifies the ideal dietary & nutrient prescription for effective weight Mx in children. This presentation draws on the experience of a clinician working in a tertiary referral setting with overweight & obese children & the current literature, to provide attendees with a dietary framework that can be implemented with overweight children in a gp setting. Susie Burrell Abbott
WA LIFESTYLE MODIFICATION for cancer & chronic diseases prevention & improved outcomes
Case study 1: Carol: a Ca diagnosis: lifestyle modifications – the why & the how Carol is a 49–year old woman attending your practice, who was diagnosed with breast cancer 9 years ago. She had a lumpectomy & axillary node sampling followed by radiotherapy, & has remained well until earlier this year, when liver metastases were diagnosed following a period when she felt ‘run down’. She is currently receiving docetaxel & Herceptin. She is thin, fit & following a Gerson diet, but has continued her 20–cigarettes a day habit. She comes to see you after reading information suggesting that nicotine may interfere with chemotherapy.
Case study 2: Garry: managing the metabolic syndrome – “tips & tricks” Garry is a 61–year old truck driver who comes to see you about prostate cancer screening, as his 85–year old father has been recently diagnosed with prostate cancer. You have been seeing him regularly for his high blood pressure & high cholesterol, both of which are now controlled with medication. He smokes 15 cigarettes & drinks 4–6 stubbies a day, does not exercise regularly & his BMI is 33. Sessions 3,6,12, S2B complements this workshop Cancer Council NSW
WB CKD 1. Haematuria & UTI
1. Haematuria & urinary infection Microscopic haematuria occurs in about 2–3% of adults. The investigation & best Mx pathway is complex & under–recognised.Symptomatic UTI is the most frequent reason why adults seek help for disease of the kidneys & urinary tract. This workshop addresses the practical issues that arise in managing these conditions. Sessions 2,7,12 Dr Meg Jardine Kidney Health Australia
WC Complementary Medicine
1. Necessary nutrients for GPs – beyond the basics An overview of important areas of nutrient shortfalls in the Australian population, focusing on iodine, vitamin D, calcium, folic acid & B12. The GP can expect to leave with knowledge of the missing nutrients, the patients that suffer from this, how to make the diagnosis, & how to restore normal nutritional levels. Dr Mark Donohoe Sessions 1,6,12 Blackmores
2. Age related macular degeneration Age related macular degeneration is the most common cause of blindness in the Western world. There is a great deal GPs can do to ensure their patients do not lose vision. 1/3 patients over the age of 75 will have some sign of the disease & will need advice on how to slow the rate of progress. 1/10 will suffer threatened vision loss & may need urgent referral. Early referral for Rx with the anti–VEGF, Lucentis, can prevent vision loss in over 80% of patients. The patient’s family will need advice on prevention & in the near future will need genetic testing. The lecture will outline the clinical picture, prognosis, risk factors, prevention & treatment of the disease. Dr Paul Beaumont Sessions 4,7,13 Blackmores
WD Stroke/TIA - optimising antiplatelet therapy in 2° prevention
This workshop will highlight the prevalence of stroke within the Australian community & the cross–risk associated with atherothrombotic disease. The interactive session will include how to risk assess patients for recurrent stroke & the antiplatelet therapies available. Dr Peter Piazza Sessions 3,4,8,9,11,12 Sanofi–Aventis
Download the pre filled out ALM registration form
